Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $2.02 per share which beat the analyst consensus estimate of $1.56 by 29.4 percent. This is a 59.06 percent increase over earnings of $1.27 per share from the same period last year. The company reported quarterly sales of $59.666 million which beat the analyst consensus estimate of $55.589 million by 7.33 percent. This is a 39.37 percent increase over sales of $42.812 million the same period last year.